The Structural Genomics Consortium, an Innovative Open-Access, Public–Private Partnership, Is a Viable Model for Drug Discovery
Mar 10, 2014
The Structural Genomics Consortium (SGC) supports drug discovery efforts through a unique, open access model of public-private collaboration. This report presents the results of an independent evaluation of the Structural Genomics Consortium, conducted by RAND Europe with the Institute on Governance. The evaluation aimed to establish the role of the SGC within the wider drug discovery and public-private partnership (PPP) landscape, assessing the merits of the SGC open access model relative to alternative models of funding R&D in this space, as well as the key trends and opportunities in the external environment that may impact on the future of the SGC. It also established the incentives and disincentives for investment, strengths and weaknesses of the SGC's model, and the opportunities and threats the SGC will face in the future. This enabled us to assess the most convincing arguments for funding the SGC at present; important trade-offs or limitations that should be addressed in moving towards the next funding phase; and whether funders are anticipating changes either to the SGC or the wider PPP landscape. Finally, we undertook a quantitative analysis to ascertain what judgements can be made about the SGC's past and current performance track record, before unpacking the role of the external environment and particular actors within the SGC in developing scenarios for the future.
The SGC in context: A review of relevant literature
The SGC as a model for investing in knowledge: Perspectives on the approach
The SGC as a model for generating knowledge: The model in practice
Extracting the value of knowledge: Outputs, outcomes and impacts of the SGC
Learning from the past to inform the future
What comes next for the knowledge platform?
Literature review material
SGC Researcher Survey Analysis